You are here: Home ยป Archives for Biotech

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

  • Funding supports next–generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug–repurposing
  • Initial clients reporting commercial success, revolutionizing indication selection of lead programs
  • Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or the “Company”), a technology–driven company that integrates mathematical algorithm–led approaches with complementary cybernetics to optimize decision–making processes, is pleased to announce the successful closing of its $10 million Seed funding round, led by third–party investor, Corvus Capital.

Sarborg has achieved significant commercial and technical milestones from its development plan, since its inception in 2024. The issuance of $10 million of Convertible Promissory Notes highlights investor confidence in Sarborg’s novel approach and rapid development delivering commercial milestones.

Looking forward, the proceeds of the fundraising will enable Sarborg to scale its AI–driven drug development and deploy agents across expanded client portfolios, while diversifying its client and equity partnership base. Sarborg will continue to deepen its intellectual property portfolio and look to broaden its agentic approach to fields beyond pharmaceuticals.

Successful Launch and Strong Commercial Validation

Sarborg has quickly capitalized on early revenue–generation, with the successful execution of an initial services agreement with a NASDAQ–listed Pharmaceutical Company, validating its core technologies and a repurposing strategy based on their lead–program drug–signature model.

Sarborg has delivered personalized dashboards to clients, a critical tool designed to provide key personnel with real–time access to data related to deliverables, research and development oversight, and drug discovery. Furthermore, Sarborg has built a proprietary portfolio of over 800 disease signatures, each uniquely mapped using its proprietary data–driven approach and now focusing on an agentic–approach to repurposing without human intervention.

Proceeds from the fundraising will be strategically deployed to:

  • Advance Sarborg’s proprietary AI agents focused on drug repurposing, target identification, and clinical trial optimization.
  • Develop novel pharmaceutical IP, transforming underused molecules into novel IP through solid–form engineering and formulation expertise.
  • Grow Sarborg’s internal pipeline of pharmaceutical assets for monetization via outlicensing or royalty–based deal structures.
  • Expand the client base and revenue–generating service business to fund ongoing innovation and reduce dilution in future rounds.

Following the demand for its seed financing, the Company expects to shortly launch a follow–on Series A financing round to enable Sarborg to scale globally and solidify its position as a category leader in AI–driven agentic innovation, combining new equity, tokenized securities and crypto–based blockchain technologies across multiple verticals.

About Sarborg Limited

Sarborg is a technology–driven company that integrates proprietary AI–agents and mathematical algorithm–based approaches with complementary cybernetics and extensive neural networks, to optimize decision–making processes. Its current principal vertical is focused on evaluating drug repurposing matching unique drug and disease signatures for pharmaceutical companies, leveraging machine learning and algorithmic strategies to enhance asset portfolio management and improve the probability of success in clinical trials. The Company is planning its expansion into further analytic areas beyond pharmaceuticals.

The company is composed of a seasoned and highly experienced team in cybernetics and signature development, drug development, medical affairs and commercialization, regulatory affairs, IP and manufacturing. Since its inception in 2024, Sarborg has applied its suite of AI agents, cybernetic algorithms, and machine learning capabilities across various sectors, enabling a highly efficient decision–making process throughout its portfolio.

Investors & Media:
[email protected]
www.sarborg.com


GLOBENEWSWIRE (Distribution ID 9519004)

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age–related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood–based biomarkers.

Minovia Chief Scientific Officer Dr. Noa Sher, commented, “We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood–based functional mitochondrial biomarkers. These biomarkers will enable identification of patients who may benefit from our mitochondrial augmentation technology, or MAT, proprietary platform, as well as patient follow–up after MAT treatment. Given how critical mitochondria are to human health, we envision a world in which assessment of mitochondrial biomarkers is available in routine checkups for individuals of all age groups. We look forward to optimizing this technology.”

In addition to the novel MAT–based mitochondrial therapies under development, Minovia has set dual goals of developing biomarkers to quantify mitochondrial content, quality and function and of using these biomarkers to determine mitochondrial scores in healthy individuals relative to mitochondrial disease patients. For this reason, Minovia opened a clinical trial in Sheba Medical Center to collect blood samples from both healthy volunteers and patients suffering from mitochondrial diseases. The Countdown for a Cure grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases, and 140 samples from healthy controls. The samples collected will be analyzed in Minovia’s labs with its newly developed biomarkers, and a “MitoScore” will be determined for each sample. In addition, the Countdown for a Cure funding will support the development of new biomarkers using novel research tools.

Mitochondrial dysfunction is known to occur in rare genetic mitochondrial diseases, as well as in chronic and age–related diseases. There is a profound unmet need for treatment of these devastating diseases, as there are currently no approved therapies for mitochondrial dysfunction and no functional tests to diagnose and quantify mitochondrial dysfunction in individuals of all ages.

The Company also recently announced entry into a definitive business combination agreement (the “Business Combination Agreement”) with Launch One Acquisition Corp. (Nasdaq: LPAA, “Launch One”), a publicly traded special purpose acquisition company. Following the expected closing of the transaction contemplated by this Business Combination Agreement (the “Business Combination”), projected for late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.

About Minovia Therapeutics

Minovia Therapeutics, chaired by John Cox, is a clinical–state biotechnology company working on treatments to replace dead or defective mitochondria with new healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Its main drug product, MNV–201, is already being tested for Pearson Syndrome and Myelodysplastic Syndrome. Minovia is also developing ways to help people live longer, healthier lives. Based in Haifa, Israel, where it operates a GMP facility for mitochondrial drug substance and drug product manufacturing for clinical trials related to its therapy, Minovia is planning to expand to the U.S. For more information, visit www.minoviatx.com.

About Countdown for a Cure

Countdown For A Cure (CFAC) is a non–profit organization dedicated to advancing mitochondrial research and medicine, improving the lives of those affected by diseases linked to mitochondrial dysfunction. Founded in 2024 by Mitzi and Jeff Solomon, who experienced mitochondrial dysfunction and its impact on their family firsthand, CFAC partners with leading research institutions and patient advocacy groups to fund cutting–edge science and provide critical support to families. Mitzi and Jeff are driven by an unwavering commitment to supporting families, accelerating research, and uniting a community determined to make a tangible difference in the lives of those affected by mitochondrial disease and all diseases connected to mitochondrial dysfunction.

About Launch One Acquisition Corp.

Launch One Acquisition Corp. is a company set up to merge with and take public an exciting business in healthcare or technology. Listed on Nasdaq under the ticker LPAA, Launch One is led by experienced leaders who want to support game–changing solutions. For more information, contact Jurgen van de Vyver at [email protected].

Additional Information and Where to Find It

In connection with the Business Combination and the Business Combination Agreement, among Launch One, Minovia and Mito US One Ltd., a newly formed Israeli company limited by shares (“Pubco”), and certain other parties named therein. Launch One and Minovia intend to file relevant materials with the U.S. Securities and Exchange Commission (“SEC”), including a Registration Statement on Form F–4 of Pubco (the “Registration Statement”), which will include a proxy statement/prospectus of Launch One, and will file other documents regarding the proposed Business Combination with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Launch One has filed or may file with the SEC in connection with the proposed Business Combination. The Registration Statement has not been filed or declared effective by the SEC. Following such filing and upon such declaration of effectiveness, the definitive proxy statement/prospectus contained within the Registration Statement and other relevant materials for the proposed Business Combination will be mailed or made available to stockholders of Launch One as of a record date to be established for voting on the proposed Business Combination.

Before making any voting or investment decision, investors and stockholders of Launch One are urged to carefully read, when they become available, the entire Registration Statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Launch One, Minovia, Pubco and the proposed Business Combination. Launch One’s investors and stockholders and other interested persons will also be able to obtain copies of the Registration Statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Launch One and/or Pubco in connection with the Business Combination, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Launch One or Minovia at the addresses set forth below.

Participants In the Solicitation

Launch One, Minovia, Pubco and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Launch One’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names, and interests in the Business Combination, of Launch One’s directors and officers in Pubco's and Launch One’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to Minovia’s directors and executive officers will also be included in the proxy statement/prospectus. You may obtain free copies of these documents as described above under the heading “Additional Information and Where to Find It.”

Non–Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Launch One, Pubco, or Minovia, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward–Looking Statements

This press release includes certain statements that may be considered forward–looking statements within the meaning of the federal securities laws. Forward–looking statements include, without limitation, statements about future events or Minovia’s, Launch One's, or Pubco's future financial or operating performance. For example, statements regarding the development and regulatory approval of MNV–201, the implications of Fast Track Designation, RPD and PRVs and the timing of future clinical trials or potential applications are forward–looking statements. In some cases, you can identify forward–looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.

These forward–looking statements regarding future events and the future results of Minovia or Launch One are based on current expectations, estimates, forecasts, and projections about the industry in which Minovia or Launch One operates, as well as the beliefs and assumptions of Minovia’s and Launch One's management. These forward–looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Launch One relating to its initial public offering filed with the SEC, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Launch One or Pubco; (ii) uncertainties; (iii) assumptions; and (v) other factors beyond Minovia’s or Launch One's control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, Minovia’s actual results may differ materially and adversely from those expressed or implied in any forward–looking statements and Minovia and Launch One therefore caution against relying on any of these forward–looking statements.

These forward–looking statements are based upon estimates and assumptions that, while considered reasonable by Minovia and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Minovia’s or Launch One's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Launch One, Minovia, Pubco, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Launch One and Minovia, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (v) projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, and the estimated implied enterprise value of Minovia; (vi) Minovia’s ability to scale and grow its business, and the advantages and expected growth of Minovia; (vii) Minovia’s ability to source and retain talent, and the cash position of Minovia following closing of the Business Combination; (viii) the ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination; (ix) the risk that the Business Combination disrupts current plans and operations of Minovia as a result of the announcement and consummation of the Business Combination; (x) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of Minovia to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (xi) costs related to the Business Combination; (xii) changes in applicable laws, regulations, political and economic developments; (xiii) the possibility that Minovia may be adversely affected by other economic, business and/or competitive factors; (xiv) Minovia’s estimates of expenses and profitability; (xv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (xvi) other risks and uncertainties set forth in the filings by Launch One and Minovia with the SEC. There may be additional risks that neither Launch One nor Minovia presently know or that Launch One and Minovia currently believe are immaterial that could also cause actual results to differ from those contained in the forward–looking statements. Any forward–looking statements made by or on behalf of Launch One or Minovia speak only as of the date they are made. Neither Launch One nor Minovia undertakes any obligation to update any forward–looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statements are based.

Contacts:

Minovia Therapeutics Ltd.
Natalie Yivgi Ohana, Co–Founder and CEO
+972–74–7039954
[email protected]

Launch One Acquisition Corp.
Jurgen van de Vyver
[email protected]
+1–510–692–9600

Investor Relations
Dave Gentry, CEO
RedChip Companies
+1–407–644–4256
[email protected]

Investor Relations
Jules Abraham
Managing Director, Communications
CORE IR
1–212–655–0924
[email protected]


GLOBENEWSWIRE (Distribution ID 9518763)

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

  • FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment
  • Significant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies and next–gen EB613 expected to enter Phase 1 in November 2025
  • Strong momentum across OPKO collaboration with obesity program showing promising preclinical data; and EB612 oral PTH directed hypoparathyroidism program candidate validation
  • Strong balance sheet provides runway through mid–Q3 2026, including dedicated OPKO collaboration funding

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

“Last week's FDA agreement on using BMD as the primary endpoint for EB613's Phase 3 program represents a pivotal milestone in our journey to bring the first oral anabolic osteoporosis tablet treatment to market,” said Miranda Toledano, Chief Executive Officer of Entera. “This unprecedented regulatory alignment validates both the strength of our clinical data and our strategic vision that began taking shape in July 2022. The concurrence opens the door to addressing a massive unmet need – with less than 25% of the world's 200 million osteoporotic women having access to safe, effective, and affordable treatment options, and no new therapies approved in this space since 2019. Beyond EB613, throughout Q2, we continued building momentum across our entire pipeline, including presenting promising pharmacokinetic data for our oral GLP–1/glucagon dual agonist program with OPKO. With our strengthened cash position of $18.9 million, including dedicated OPKO collaboration funding, we are well–positioned to execute on multiple value–creating milestones across 2025 and beyond.”

Key Recent Highlights

EB613: First Oral PTH(1–34) Anabolic Treatment for Osteoporosis

  • FDA Agreement that BMD Primary Endpoint Would Support NDA: In a July Type A meeting, FDA provided written concurrence on our Phase 3 study design – a single multinational, randomized, double–blind, placebo–controlled, 24–month study in women with postmenopausal osteoporosis, where change in total hip BMD is evaluated as the primary endpoint, and incidence of new or worsening vertebral fractures is evaluated as the key secondary endpoint. As a 505(b)(2) application, the submission will rely on FDA's previous findings of effectiveness and safety for the Reference Listed Drug Forteo®, where the correlation between BMD and fracture has been well–established. The study is designed and powered to demonstrate a statistically significant increase in total hip BMD, coupled with a positive trend on vertebral fracture reduction as key secondary endpoint to provide substantial evidence of effectiveness. This FDA decision is independent of the Agency's qualification of the SABRE BMD Initiative which is still expected within 2025.
  • Regulatory Burden Significantly Reduced: In May and June, Entera received written agreements from FDA that dedicated oral carcinogenicity studies and comprehensive nonclinical developmental and reproductive toxicity (DART) studies are not warranted given the totality of evidence generated fromForteo® literature and nonclinical studies conducted with EB613.
  • Strong Clinical Data Gains Scientific Recognition: In April, Dr. Rachel B Wagman presented early effects of EB613 on trabecular and cortical bone using 3D–DXA at the 2025 WCO–IOF–ESCEO Congress. Additionally, 3D Shaper Phase 2 data was selected for oral presentation at ASBMR 2025 in September.
  • Next–Generation EB613 Advancing: “Advancing Oral Anabolic Treatments for Osteoporosis: Pre–Clinical Data for Next Gen EB613 Tablet Utilizing N–Tab™ Proprietary Technology” was selected for poster presentation at ASBMR 2025. Next Gen EB613 is being developed with a new generation of Entera's N–TAB™ platform and is expected to enter the clinic in a Phase 1 Safety and PK Study in November 2025.
  • Strategic Regulatory Engagement: In June, CEO Miranda Toledano participated in the Boston “CEO Forums: An FDA Listening Tour to Engage Pharma and Bio CEOs” and presented a one–minute brief on osteoporosis and potential regulatory reform to spur innovation.

First PTH (1–34) Tablet Protein Replacement Therapy for Hypoparathyroidism

  • First pre–clinical PK/PD data from undisclosed collaborative research with long–acting PTH agonist as a once–daily tablet format is expected by end of year.

OPKO Health Collaboration Programs

  • First GLP–1/Glucagon Agonist (Oxyntomodulin) Peptide Tablet Candidate for Obesity: In June, a poster at ENDO2025 reported PK data from a mini–pig study of oral OPK–88006 (dual GLP–1/glucagon receptor agonist in partnership with OPKO Health, Nasdaq: “OPK”) which showed plasma levels consistent with those reported in humans for the highest subcutaneous dose of Wegovy™ (semaglutide) weekly injection, a standard of care for the treatment of obesity. The reported pharmacological data supports a once–daily tablet regimen of this first–in–class oral dual agonist. A Phase 1 study is being planned and IND filing is expected in H1 2026.
  • First GLP–2 Peptide Tablets for Short Bowel Syndrome: In June, Entera in partnership with OPKO's “First–in–Class Oral GLP–2 Analog for Treatment of Short Bowel Syndrome” abstract was selected for poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress.

Financial Results for the Quarter Ended June 30, 2025

Cash and cash equivalents were $18.9 million as of June 30, 2025, including $8.0 million in restricted cash designated to fund the OPKO collaboration through Phase 1 studies of oral GLP–1/glucagon candidate OPK–88006. Cash on hand is expected to support operations through mid–third quarter 2026.

Net loss was $2.7 million, or $0.06 per ordinary share, for the three months ended June 30, 2025, compared to $2.1 million, or $0.06 per ordinary share, for the three months ended June 30, 2024.

Research and development expenses were $1.5 million for the three months ended June 30, 2025, compared to $1.1 million for the three months ended June 30, 2024, an increase of $0.4 million. The increase was primarily due to regulatory activities and Phase 3 planning for EB613.

General and administrative expenses were $1.1 million for the three months ended June 30, 2025, compared to $1.1 million for the three months ended June 30, 2024.

Total operating expenses were $2.7 million for the three months ended June 30, 2025, compared to $2.2 million for the three months ended June 30, 2024.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and a pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34)teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 with alignment from FDA on the use of BMD as its primary endpoint. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

 
ENTERA BIO LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
 
       
  June 30,   December 31,
  2025   2024
  (Unaudited)   (Audited)
   
Cash and cash equivalents 10,858   8,660
Accounts receivable and other current assets 438   312
Restricted cash 8,015   –
Property and equipment, net 79   57
Other assets 277   361
Total assets 19,667   9,390
 
 
Accounts payable and other current liabilities 1,844   1,176
Total non–current liabilities 567   134
Total liabilities 2,411   1,310
Total shareholders' equity 17,256   8,080
       
Total liabilities and shareholders' equity 19,667   9,390

   
ENTERA BIO LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)

(Unaudited)

  
  Three Months Ended
June 30,
  2025   2024
REVENUES –   57
COST OF REVENUES –   49
GROSS PROFIT –   9
OPERATING EXPENSES:    
Research and development 1,520   1,086
General and administrative 1,148   1,088
TOTAL OPERATING EXPENSES 2,668   2,174
OPERATING LOSS 2,668   2,165
FINANCIAL INCOME, NET (12)   (20)
NET LOSS 2,656   2,145
     
LOSS PER SHARE BASIC AND DILUTED 0.06   0.06
       
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE 46,836,700   37,090,160
     


GLOBENEWSWIRE (Distribution ID 9509020)

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal that the NDA marketing application filing for EB613 would be supported by a single multinational, randomized, double–blind, placebo–controlled, 24 month phase 3 study in women with postmenopausal osteoporosis, where change in total hip BMD is evaluated as the primary endpoint, and incidence of new or worsening vertebral fractures is evaluated as the key secondary endpoint. This marks a shift from precedent placebo–controlled phase 3 studies of new osteoporosis drugs which required incidence of fracture as the primary endpoint.

“This regulatory update is a major milestone for Entera and the entire osteoporosis community,” said Miranda Toledano, CEO of Entera. “Our alignment with the FDA reflects the strength of our data and collaborative discussions. Importantly, it allows us to advance our clinical development program without having to wait for FDA’s qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE), which is still expected this year. We thank the FDA and the Review Team at the Division of Endocrinology for their constructive approach. We also thank the SABRE team for paving the path to innovation for osteoporosis treatment,” said Toledano.

“Osteoporosis afflicts more women than heart attack, stroke and breast cancer combined. Over 200 million women globally are estimated to have osteoporosis and remain vastly undertreated, despite efficacious injectable anabolic (bone forming) treatments. One in two women over the age of 50 will suffer a fracture due to osteoporosis. No new drug for osteoporosis has been approved by FDA since 2019; and innovation has stalled for close to a decade due to the size, duration, cost and ethical constraints associated with fracture endpoint studies. In a silent disease, patient and clinician access to novel and alternative forms of validated mechanisms of action is important. We are developing EB613 as the first oral, once–daily anabolic tablet treatment to potentially serve this unmet medical need. EB613 is intended to increase skeletal mass, improve bone microarchitecture and reduce the risk of fracture,” said Miranda Toledano, CEO of Entera.

About EB613

Substantial evidence supports the efficacy of anabolic therapies over bisphosphonates for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1–34), teriparatide), is being developed as the first oral, once–daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6–month, 161–patient, placebo–controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose–proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D–DXA showed increases with EB613 compared with placebo in a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with those of published subcutaneous teriparatide at the 6–month time point. Further abstracts have been submitted to ASBMR and NAMS 2025 conferences.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo–controlled, dose–ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP–2 peptide as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

About SABRE

The Study to Advance BMD as a Regulatory Endpoint (SABRE) initiative, which started as a public private partnership sponsored by the FNIH in 2013, has amassed the strongest evidence to date that treatment–related gains in Bone Mineral Density (BMD) reliably and quantitatively predict fracture–risk reduction. In November 2023, the SABRE team submitted a full qualification package to FDA’s Biomarker Division as part of the Drug Development Tool Biomarker Qualification Pathway to potentially qualify BMD as a surrogate endpoint to fracture; in March 2024, the FDA Biomarker Division indicated to the SABRE project team that a decision would be issued within 10 months. The single most important predictor of osteoporotic fractures in postmenopausal women without a previous fracture is BMD. Treatment guidelines in the U.S. strongly recommend pharmacologic therapy for patients with a BMD T–score of –2.5 or lower in the spine, femoral neck, total hip. SABRE final FQP meta–analysis included data from 22 randomized, placebo–controlled trials (63,000 participants across seven drug classes) and showed that treatment–related gains in total–hip BMD explain 72% of the observed fracture–risk reduction. The R2 for this correlation was 0.73—double the correlation between blood pressure and stroke (R² = 0.37), which is the well accepted basis for the value of antihypertensive therapy.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9501141)

Veteran Global Health Leader, Dr. Rebecca Martin, Named President of Global Immunization at Sabin

WASHINGTON, July 21, 2025 (GLOBE NEWSWIRE) — Renowned global health expert Rebecca Martin, PhD, recognized internationally for her leadership in developing and implementing immunization programs and strengthening health systems, joins the Sabin Vaccine Institute today as President of Global Immunization, assuming the reins of the nonprofit’s efforts in vaccination innovation and extending vaccine access.

Martin most recently served as Vice President for Global Health at Emory University, and as the Director of the Emory Global Health Institute, following a 24–year career with the US Centers for Disease Control and Prevention (CDC). She is also an adjunct professor in the Department of Global Health at Emory. She brings decades of successful partnering with global, regional and country–level health leaders in infectious disease prevention, as well as in–country experience leading low– and middle–income country (LMIC) health and immunization initiatives.

Her extensive CDC career includes ten years working in Kenya, Tanzania, and Denmark, seconded to the World Health Organization African and European regions. In her four years in Nairobi, Kenya, she provided technical expertise to eight East African countries focused on vaccine–preventable disease surveillance, prevention and elimination strategies and policies, and new vaccine introductions. For several years in Dar as Salaam, Tanzania, she led surveillance and workforce development for CDC as part of the President’s Emergency Plan for AIDS Relief (PEPFAR), and supervised staff in surveillance, health management information systems (HMIS), monitoring and evaluation (M&E), and human capacity development for CDC HIV/AIDS programs.

Currently, she serves as the Vice–Chair for WHO Regional Office for Africa (AFRO) Emergency Preparedness & Response Technical Advisory Group (EPR–TAG), an independent advisory group providing strategic guidance on all matters pertaining to public health emergency preparedness and response in Africa.

“With her global, country and local–level experience, Rebecca has the first–hand expertise needed to address today’s challenging immunization landscape, and more importantly, to co–create new solutions with public and private partners to boost lagging immunization rates and prevent human suffering,” says Sabin CEO Amy Finan. “She is an outstanding addition to Sabin’s executive team and will lead Sabin’s global immunization work as we continue to respond to the needs of individual countries and help shape new global strategies with partners to increase access and uptake of vaccines.”

Martin calls her new role a “full circle” moment.  

“I am honored and excited to join the Sabin Vaccine Institute as President of Global Immunization, bringing my experience, knowledge, and commitment to Sabin's critical mission in making vaccines available to everyone, everywhere,” she says.

“I am thrilled to work with the dedicated colleagues at Sabin who are passionate about tackling vaccine–preventable diseases through collaboration with stakeholders from multiple sectors in addition to health,” she adds. “There is no moment more urgent than now to innovate and double down on our efforts to prevent illness and save lives through immunization.”

Sabin’s Global Immunization team works with local and national governments and academic, global, and philanthropic partners to put communities at the heart of solutions that tackle urgent vaccination challenges, with a renewed focus to bolster the falling coverage in childhood routine immunization and support life–course immunization. In 2023, almost 14.5 million children received no vaccinations, according to WHO, an increase of 2.7 million more children compared to 2019.

The Sabin team brings expertise across the immunization spectrum, including building global communities of practice, identifying barriers and creating solutions to improve vaccine access and delivery of current and new vaccines, and conducting epidemiological research to support immunization. Sabin’s skills are applied to multiple infectious diseases, including HPV, typhoid, cholera, rotavirus, COVID–19 and malaria. Additional work includes efforts to immunize zero–dose children and transition to hexavalent vaccines in national immunization programs.

During her tenure at Emory, Martin built and aligned multidisciplinary global health infrastructure, fostered global collaborations across health organizations, led interdisciplinary global health research and worked to build the next generation of global health leaders. She was also a member of Emory’s Woodruff Health Sciences Center leadership team.

Martin’s most recent role with the CDC was Director of the Center for Global Health, then the largest operating unit at the CDC. Her achievements include leading the CDC's global efforts across disease initiatives and through the start of the global health security agenda, including polio eradication and disease control acceleration and elimination for vaccine–preventable diseases, malaria elimination, ending HV epidemics, and strengthening health systems to detect and respond to disease threats and emergencies.

Martin received her Doctor of Philosophy from the Johns Hopkins Bloomberg School of Public Health in international health with a focus on infectious disease epidemiology. She has co–authored manuscripts and developed strategic plans, normative guidance and guidelines on immunization strategies, vaccine–preventable diseases and surveillance methods for both immunization and HIV, and for global health security.

About the Sabin Vaccine Institute 
  
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a nonprofit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X @SabinVaccine. 

Media Contact:
Monika Guttman
Senior Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 621–1691
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/05fb30d1–3f58–4240–aafe–91d33dab3398


GLOBENEWSWIRE (Distribution ID 9497738)

علم Superhumans الجديد: نظام الذكاء الاصطناعي BioSport™ يكشف النقاب عن الإمكانات الرياضية الخفية

كالجاري، ألبرتا ونيويورك, July 16, 2025 (GLOBE NEWSWIRE) —

 في خطوة تشير إلى عصر جديد في علم السلامة والأداء الرياضي، كشفت شركة BioSport™ Health Inc، المتخصصة في بتقنيات دقيقة للرعاية الصحية، اليوم عن هيئة استشارية عالمية تابعة لها – مجموعة متنوعة من نخبة الرياضيين والعلماء والمديرين الماليين – للمساعدة في توجيه إطلاق منصتها العالمية القادمة المقرر في خريف 2025.

في عالم رياضات النخبة المحفوف بمخاطر كبيرة، قد يتوقف الفرق بين الانتصار والهزيمة على عيب بيولوجي واحد غير ظاهر. خطر خفي بوجود مشاكل في القلب. التهاب مزمن. استعداد وراثي للإصابة. فهذه التهديدات الصامتة قد أنهت مسيرات رياضية وحيوات واعدة – كانت تحدث أحيانًا على الهواء مباشرة أمام ملايين المشاهدين. ورغم عقود من التقدم في مجالات التدريب والطب الرياضي والأجهزة القابلة للارتداء، إلا أن اللاعبين الرياضيين في أمريكا وحول العالم لا يزالون يتعرضون لنفس المشاكل المتكررة: الإصابات الناتجة عن فرط الإجهاد ومضاعفات أمراض القلب ونقاط القوة أو الضعف غير المكتشفة. وغالبًا ما يُخمّن المدربون الجداول الزمنية للتعافي. فيما تعتمد اختيارات أعضاء الفرق على المقاييس السطحية للأداء. حتى الرياضيون المتميزون نادرًا ما يكونون على دراية بالطبيعة الحقيقية لأجسامهم – أو كيفية حماية هذه الموهبة البيولوجية.

تعتمد منصة BioSport™ على أسس علم الجينوم وتحليل الميكروبيوم والذكاء الاصطناعي وتعد بمعالجة بعض المشكلات الأكثر إلحاحًا وتكرارًا في الألعاب الرياضية:

  • الإصابات المرتبطة بفرط الإجهاد بما فيها؛ تمزق الرباط الصليبي الأمامي والهدم العضلي والكسور الناجمة عن الإجهاد.
  • الأحداث القلبية المفاجئة لا تزال السبب الرئيسي للوفاة بين اللاعبين الرياضيين أثناء اللعب.
  • عدم المساواة في اختيار اللاعبين بسبب مقاييس الأداء القديمة.
  • وغياب الإلمام بالإمكانات البيولوجية الحقيقية للاعب على نطاق واسع.

من جهته أردف الدكتور Anmol S. Kapoor، طبيب أمراض القلب ومؤسس شركة Kapoor Wealth Partners، وهي شركة استشارات واستثمارات للجيل القادم من أبوظبي قائلاً: “رغم كل هذه التقنيات المتاحة في المساحات المحيطة بالملاعب، لا يزال اللاعبون الرياضيون يتساقطون”. “لقد عكفنا على علاج الأعراض واتباع أسلوب التخمين في الفترات اللازمة للتعافي. ما نحتاجه هو خريطة بيولوجية متكاملة – رعاية مُخصصة تعتمد على بنية جسم كل لاعب رياضي. وهذا هو ما تقدمه BioSport™.”

منصة دقيقة من أجل مستقبل الرياضة

توجد BioFit Score في صميم منصة The BioSport™، وهي ذات براءة اختراع مُعلقة وتحلل ما يزيد عن 15,000 متغير وراثي بشري إلى جانب بيانات ميكروبيوم الأمعاء لتقييم:

  • خطر الإصابة
  • القدرة على التعافي
  • الاستعدادت القلبية
  • القدرة على التحمل والطاقة الكامنة
  • مؤشرات الإجهاد الذهني
  • الحالات الهرمونية والالتهابية

تم جمع هذه المعلومات بواسطة PanOmiQ™ لدى BioAro Inc، وهي أسرع منصة MultiOmics مدعومة بالذكاء الاصطناعي في العالم ومدمجة مع أجهزة جمع البيانات (معدل ضربات القلب، والنوم، وحجم العمل) القابلة للارتداء ويتم تسليمها من خلال لوحات معلومات سهلة الاستخدام وتطبيقات الأجهزة المحمولة للاعبين.

الهدف: تمكين اللاعبين الرياضيين والمدربين والفرق الطبية من اتخاذ قرارات فورية ودقيقة فيما يتعلق بالتدريب والتغذية والراحة والمخاطرة. حيث يمكن بالاستعانة بالذكاء الاصطناعي وبيانات الأجهزة القابلة للارتداء أن يُحوّل جهاز BioSport™ هذه البيانات إلى تقارير وتوصيات فورية. والنتيجة؟ يُمكن للمدربين واللاعبين الرياضيين تعديل الحمل التدريبي ورصد العلامات التحذيرية وتحسين التغذية بناءً على الخصائص البيولوجية الفريدة لكل رياضي—وليس بناءً على معادلات عامة.

وفي هذا الصدد قال Patrick Kirkwood الرئيس التنفيذي لشركة BioSport™ Health Inc “اعتبره جهاز GPS لجسمك”. “فنحن نمنح اللاعبين الرياضيين خريطة طريق لبلوغ القمة— وتجنب الانزلاق إلى الهاوية.”

مجلس عالمي يتمتع بخبرات عريضة في مجالات الرياضة والعلوم والإستراتيجيات

ولدعم هذا الطرح الطموح، قامت BioSport™ بتعيين مجلس استشاري عالمي قوي:

  • Grant Fuhr – حارس مرمى Hall of Fame في دوري الهوكي الوطني (NHL) والمتوج بكأس ستانلي خمس مرات
  • Christina Nathalie Smith لاعبة أولمبية شابة (OLY) – رائدة الزلاجات الجماعية الأولمبية
  • Nik Lewis –لاعب Hall of Famer في دوري كرة القدم الكندي وصاحب الرقم القياسي في مهارات الاستقبال على مر العصور
  • Paul O’Donoghue – رائد أعمال في مجال الطاقة والتكنولوجيا وخبير إستراتيجي بالأعمال
  • H.E. Prof. Dr. Zahid Haque– دبلوماسي الرياضة العالمية ومناصر لمكافحة المنشطات
  • Kurt Soost – محلل مالي معتمد (CFA) – مدير استثمار مخضرم وخبير في أسواق رأس المال
  • Nick Wilson لاعب أوليمبي شاب (OLY) – رياضي أولمبي وخبير إستراتيجي يتمتع بكفاءة عالية

يقول Grant Fuhr، حارس مرمى Hall of Famer دوري الهوكي الوطني (NHL)، والذي واجه ضغوط رياضة النخبة بصورة مباشرة: “هذا النوع من المنصات يُغيّر حياة الأشخاص. “فالأمر لا يقتصر على الأداء فحسب – بل يتعلق بإدراك المخاطر قبل فوات الأوان. فهذه المنصة لم تكن متاحة لجيلنا. واللاعبين بحاجة إليها حاليًا. BioSport™ هو الابتكار الذي كنت أتمنى أن نحظى به عندما كنت لاعبًا.”

حتى مع ظهور الأجهزة القابلة للارتداء وتطبيقات التدريب ومختبرات العلوم الرياضية، لا تزال هناك نقطة عمياء رئيسية: التفرد البيولوجي.

وفقًا لبيانات الطب الرياضي الأمريكية الحديثة:

  • تشكل الإصابات الناتجة عن فرط الإجهاد أكثر من 35% من الزيارات الطبية ذات الصلة بالألعاب الرياضية.
  • يظل توقف القلب المفاجئ السبب الرئيسي للوفاة بين اللاعبين الرياضيين الشباب ولا سيما في الرياضات عالية الشدة.
  • يرتبط التخصص المبكر بشكلٍ مباشر بالإرهاق والألم المزمن الذي يحدث في أواخر مرحلة المراهقة.

يقول Patrick Kirkwood: “لا يوجد نموذج واحد يناسب الجميع في البيولوجيا البشرية”. “فقد يكون أمامنا لاعبان رياضيان متطابقان نظريًا، لكن أحدهما قد يكون عرضة للإصابة أو إجهاد القلب بيولوجيًا. وهنا تبرز أهمية هذه المنصة—فهي تضفي وضوحًا على هذه الفوضى.”

تهدف الشركة إلى إرساء معيار عالمي جديد في مجال الصحة الرياضية، ولا يقتصر الأمر على المحترفين، بل يمتد ليشمل الشباب والهواة واللاعبين الرياضيين الجامعيين أيضًا. وقد دخلت منصة BioSport™ حاليًا في مرحلة الاستخدام التجريبي لدى مجموعة مختارة من الأندية المحترفة ومراكز التدريب الأولمبية وأكاديميات الشباب. ومن المقرر إطلاقها على نطاق واسع في خريف 2025 مستهدفةً أسواق أمريكا الشمالية وأوروبا والشرق الأوسط وآسيا والمحيط الهادئ.

تشمل مميزات المنصة ما يلي:

  • مجموعات اختبار الجينوم والميكروبيوم (للاستخدام في العيادات أو المنازل)
  • لوحات بيانات مدمجة بالذكاء الاصطناعي للاعبين الرياضيين والمدربين
  • تطبيقات الأجهزة المحمولة للتعافي والتخطيط الشخصي
  • بوابات إلكترونية للأطباء وإمكانية إجراء فحص عن بُعد من متخصصي الجينوم
  • وحدات متكاملة قابلة للارتداء لمراقبة الأداء بشكل مستمر

وأضاف الدكتور Kapoor: “إن BioSport™ ليس مجرد أداة صحية، بل هو شبكة أمان للأفراد المعرضين لمخاطر صحية عالية. فنحن نبني مستقبلاً لا يُبعد فيه أحد عن المنافسة بسبب مرض يمكن الوقاية منه”.

لا يقتصر دور BioSport™ على مساعدة اللاعبين الرياضيين في مطاردة الميداليات الذهبية، بل يساعدهم أيضًا في مواصلة مسيرتهم الرياضية وأحلامهم ومستقبلهم. فالأمر يتعلق بـ Powering Superhumans™.

حول BioSport™

BioSport™ هي شركة من الجيل الجديد متخصصة في تقنيات الصحة الرياضية، يقع مقرها في كندا والولايات المتحدة وتُركز على تحسين أداء اللاعبين الرياضيين وإطالة مسيرتهم الرياضية من خلال علم الجينوم وذكاء الميكروبيوم والتخصيص المعزز بالذكاء الاصطناعي. وتدعم المنصة الحقوق الخاصة للملكية الفكرية والشراكات العالمية والرؤيةً اللازمة لوضع معيار عالمي جديد في مجال المعلومات المتعلقة بصحة الرياضيين.

سفير علامة BioSport™

Hayden Mayeur

حائز على ميداليتين في بطولة العالم وبطل كندا الحالي في بطولة الانطلاق الجماعي للرجال

جهة الاتصال الإعلامية

[email protected]
www.theBioSport.com

تتاح الصور المرافقة لهذا الإعلان على

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cf136e9–2de5–4dbf–9cf1–91b3d4a6ff73

https://www.globenewswire.com/NewsRoom/AttachmentNg/d90ca089–d861–4ad1–aa94–a106e3bb5f1b


GLOBENEWSWIRE (Distribution ID 9494029)

The New Science of Superhumans: The BioSport™ AI System Unlocks Hidden Athlete Potential

CALGARY, Alberta and NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — In a move that signals a new era in athlete safety and performance science, The BioSport™ Health Inc, a precision health technology company, today unveiled its Global Advisory Board—a diverse group of elite athletes, scientists, and financial leaders—to help guide its upcoming global platform launch set for Fall 2025.

In the high–stakes world of elite sports, the difference between triumph and tragedy can hinge on a single, unseen biological flaw. A hidden cardiac risk. A lingering inflammation. A genetic predisposition to injury. These silent threats have ended promising careers and lives—sometimes on live television, in front of millions. Despite decades of progress in training, sports medicine, and wearables, athletes in America and around the world are still falling victim to the same recurring issues: overexertion injuries, cardiac complications, and unidentified physical strengths or weaknesses. Coaches often guess at recovery timelines. Team selections rely on surface performance metrics. Even top athletes rarely know what their bodies are truly built for—or how to protect that biological gift.

Built on a foundation of genomics, microbiome analysis, and artificial intelligence, The BioSport™’s platform promises to tackle some of the most urgent and persistent problems in athletics:

  • Overexertion–related injuries, including ACL tears, muscle breakdown, and stress fractures.
  • Sudden cardiac events, still the leading cause of death among athletes during play.
  • Inequities in athlete selection, driven by outdated performance metrics.
  • And the widespread lack of awareness around an athlete’s true biological potential.

“Despite all the technology on the sidelines, athletes are still breaking down,” said Dr. Anmol S. Kapoor, a Cardiologist and Founder of Kapoor Wealth Partners, a next–generation wealth advisory and investment firm from Abu Dhabi. “We’ve been treating symptoms and guessing recovery times. What we need is a biological blueprint—customized care based on what each athlete’s body is built for. That’s what The BioSport™ delivers.”

A Precision Platform for the Future of Sport

At the core of The BioSport™ platform is the BioFit Score, a patent–pending tool that analyzes over 15,000 human genetic variants alongside gut microbiome data to evaluate:

  • Injury risk
  • Recovery capacity
  • Cardiac predispositions
  • Endurance and power potential
  • Mental stress markers
  • Hormonal and inflammatory states

This information is synthesized by PanOmiQ™ of BioAro Inc, World’s Fastest AI powered MultiOmics Platform, integrated with wearable data (HRV, sleep, workload), and delivered through easy–to–use dashboards and athlete mobile apps.

The goal: to empower athletes, coaches, and medical teams to make real–time, precision–based decisions around training, nutrition, rest, and risk. Using AI and data from wearables, The BioSport™ transforms these layers into real–time reports and recommendations. The result? Coaches and athletes can adjust training loads, spot warning signs, and optimize nutrition based on the athlete’s unique biology—not generic formulas.

“Think of it as GPS for your body,” says Patrick Kirkwood, CEO of The BioSport™ Health Inc. “We give athletes a roadmap to reach their peak—and avoid the cliffs.”

A Global Board with Deep Roots in Sport, Science & Strategy

To support this ambitious rollout, The BioSport™ has appointed a powerhouse Global Advisory Board:

  • Grant Fuhr – NHL Hall of Fame goalie and 5x Stanley Cup Champion
  • Christina Nathalie Smith, OLY – Olympic bobsleigh pioneer
  • Nik Lewis – CFL Hall of Famer and all–time receptions leader
  • Paul O’Donoghue – Energy and tech entrepreneur, corporate strategist
  • H.E. Prof. Dr. Zahid Haque – Global sports diplomat and anti–doping advocate
  • Kurt Soost, CFA – Veteran investment executive and capital markets expert
  • Nick Wilson, OLY – Olympian and high–performance strategist

“This is the kind of platform that changes lives,” said Grant Fuhr, NHL Hall of Famer goalie, who faced the pressures of elite sport firsthand. “It’s not just about performance—it's about knowing your risks before it's too late. We didn’t have this in my day. Athletes need it now. The BioSport™ is the innovation I wish we had when I played.”

Even with the rise of wearable devices, training apps, and sports science labs, there’s a major blind spot: biological individuality.

According to recent U.S. sports medicine data:

  • Overexertion injuries account for over 35% of sports–related medical visits.
  • Sudden cardiac death remains the leading cause of mortality in youth athletes, particularly in high–intensity sports.
  • Early specialization has been directly linked to burnout and chronic pain by late adolescence.

“There’s no one–size–fits–all in human biology,” said Patrick Kirkwood. “Two athletes may look identical on paper, but one could be biologically prone to injury or cardiac strain. That’s why this platform matters—it brings clarity to the chaos.”

The company aims to set a new global standard in sports health, not just for professionals but for youth, amateur, and collegiate athletes as well. The BioSport™ platform is currently in pilot use with select professional clubs, Olympic training centers, and youth academies. A full–scale launch is scheduled for Fall 2025, targeting markets across North America, Europe, the Middle East, and Asia–Pacific.

Platform features include:

  • Genomic and microbiome test kits (clinic or home use)
  • AI–integrated dashboards for athletes and coaches
  • Mobile apps for personalized recovery and planning
  • Physician portals and teleconsultation access with genomics specialists
  • Wearable integrations for continuous performance monitoring

“The BioSport™ isn’t just a health tool—it’s a safety net for high–risk individuals,” added Dr. Kapoor. “We’re building a future where no one gets sidelined because of something preventable.”

The BioSport™ isn’t just helping athletes chase gold—it’s helping them keep their careers, their dreams, and their futures intact. It’s about Powering Superhumans™.


About The BioSport™

The BioSport™ is a Canada– and U.S.–based next generation sports health technology company focused on enhancing athlete performance and longevity through genomics, microbiome intelligence, and AI–powered personalization. The platform is backed by proprietary IP, global partnerships, and a vision to create the new global standard in athlete health intelligence.

The BioSport™ Brand Ambassador

Hayden Mayeur

Two–Time World Championship Medalist & Canada's Reigning Men's Mass Start Champion

Media Contact

[email protected]
www.theBioSport.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cf136e9–2de5–4dbf–9cf1–91b3d4a6ff73

https://www.globenewswire.com/NewsRoom/AttachmentNg/d90ca089–d861–4ad1–aa94–a106e3bb5f1b


GLOBENEWSWIRE (Distribution ID 9494030)

الإمارات العربية المتحدة تعتمد المكمل Longevity+ من BioAro، فاتحة المجال إلى إمكانات تسويقية كبيرة في مجال الصحة الوقائية العالمية

كالجاري، ألبرتا, July 08, 2025 (GLOBE NEWSWIRE) — في خطوة مهمة تربط بين التكنولوجيا الحيوية والصحة الوقائية واتجاهات العافية العالمية، أعلنت شركة التكنولوجيا الحيوية الكندية BioAro عن إطلاق أول منتج غذائي علاجي لها ضمن خط المكملات الجديد: Longevity+™، وهي كبسولة مُنتظر حصولها على براءة اختراع ومُصممة علميًا لدعم الشيخوخة الصحية من خلال التكامل التآزري متعدد الجزيئات. وبعد الحصول على الموافقات اللازمة في دولة الإمارات العربية المتحدة، أصبحت شركة BioAro الآن على أهبة الاستعداد للتوسع في أمريكا الشمالية وأوروبا والمملكة المتحدة وبلدان أخرى.

يأتي إطلاق مكمل Longevity+™ في وقتٍ حيوي، حيث من المتوقع أن يتجاوز سوق إطالة العمر والشيخوخة الصحية العالمي 44 مليار دولار أمريكي بحلول عام 2030، مدفوعًا بالطلب المتزايد على المكملات الغذائية العلاجية المتقدمة التي تتجاوز مفهوم المكملات الأساسية. دخول BioAro إلى هذا المجال ليس بالخبر العادي. فهو يعني الجمع بين أحدث الأبحاث والرؤى السريرية وتقنيات تحليلات البيانات البيولوجية المتعددة – وهي سمات مميزة لأصولها في مجال التكنولوجيا الحيوية – لتقديم منتج قائم على العلم، لا على المبالغة.

بروتوكول متكامل ومبتكر لإطالة العمر

ما يميز Longevity+™ ليس تركيبته فحسب، بل فلسفته أيضًا: حيث تلتقي البساطة بالتآزر. تحتوي كل جرعة يومية (كبسولتان) على مزيج قوي من أحادي نيوكليوتيد النيكوتيناميد (NMN)، والريسفيراترول، والإنزيم المساعد Q10، والكركمين، وفيتامين د، وفيتامين ب12 – وهي جزيئات تدعم كل منها على حدة طاقة الخلايا، وصحة الميتوكوندريا، وتعديل الاستجابة الالتهابية، والنشاط الذهني. ولكن عند تناولها معًا بنسبة مُصممة بدقة، تشير الأبحاث العلمية المبكرة إلى أنها قد تُحدث تأثيرات تآزرية تُعزز فوائدها الفردية، مما قد يُوفر مسارًا متكاملًا لإطالة العمر الصحي.

صرح الدكتور Anmol Kapoor، مؤسس BioAro: “لا نريد أن نكون مجرد شركة مكملات أخرى”. “تركيبتنا إنما هي نتاج سنوات من البحث الصحي الدقيق في علم الجينوم، وعلم الأيض، والطب الشخصي. لقد صممنا Longevity+ من منظور بيولوجيا الأنظمة، مع التركيز على كيفية تفاعل الجزيئات – وليس فقط على كيفية عملها بمفردها.”

من المختبر إلى الحياة: طموح عالمي لشركة كندية في مجال التكنولوجيا الحيوية

استنادًا إلى تاريخ BioAro في التشخيص الدقيق وتقنيات تحيليلات البيانات البيولوجية المتعددة القائمة على الذكاء الاصطناعي، يمثل خط المكملات أول منتج من المكملات الصحية موجه للمستهلك تطلقه الشركة، حيث يحول سنوات من البحث المعقد إلى بروتوكول يومي بسيط.

شركة BioAro بصدد إتمام شراكات توزيع في أمريكا الشمالية وأوروبا والمملكة المتحدة والهند وجنوب شرق آسيا تزامنًا مع الحصول على التصاريح التنظيمية والموافقة على تسويقه في دولة الإمارات العربية المتحدة، إحدى أكثر أسواق العالم تقدمًا في مجال ابتكارات الصحة والعافية. كما تخطط الشركة لدمج Longevity+ في برامجها السريرية لإطالة العمر، بما في ذلك التقييمات الصحية الشخصية وأدوات مراقبة الصحة رقميًا، مما يُشكل منظومة متكاملة للراغبين في إدارة الشيخوخة والحيوية بشكل استباقي.

أهمية وفعالية مكونات المنتج

* NMN (أحادي نيوكليوتيد النيكوتيناميد): من الطلائع الحيوية لإنزيم NAD+، والذي يُعد ضروريًا لصحة الميتوكوندريا وإصلاح الخلايا.

* الريسفيراترول: بوليفينول معروف بقدرته على تنشيط السرتوينات ومحاكاة فوائد تقييد السعرات الحرارية.

* تميم الإنزيم Q10: ضروري لسلامة القلب وأيض الطاقة، وخاصةً لدى كبار السن.

* الكركمين: مركب قوي مضاد للالتهابات ومضاد للأكسدة مستخلص من الكركم.

* فيتامين د وب12: ضروريان لتعديل الاستجابة المناعية والصحة العصبية الذهنية والتوازن الأيضي.

تمثل هذه التركيبة تحولًا نحو التفكير على مستوى أنظمة الجسم في المكملات – حيث لا يتمثل الهدف في تحميل الجسم بعناصر غذائية معزولة، بل استعادة الانسجام على المستوى الجزيئي.

قيد الحصول على براءة اختراع ومعزز بقوة الأداء

يخضع Longevity+™ حاليًا لمراجعة الحصول على براءة اختراع لتركيبته المبتكرة وآلية توصيله، حيث تستفيد BioAro من أبحاثها الخاصة في تحسين امتصاص العناصر الغذائية والتوافر البيولوجي. إن الدراسات السريرية التجريبية هي الآن في مراحل التخطيط في جميع أنحاء كندا والإمارات العربية المتحدة، مع التركيز على تتبع المؤشرات الحيوية للتحقق من صحة النتائج في فئات المستخدمين على أرض الواقع.

إعادة تعريف مستقبل الشيخوخة

مع دخول BioAro في مجال المكملات التي تساعد على إطالة العمر، لا تخطط الشركة لبيع المكملات فقط، بل إنها تعمل على تشكيل تصور جديد حول الشيخوخة، حيث تجتمع الوقاية مع الأداء، وحيث تحل الاستراتيجيات القائمة على أسس علمية محل نصائح العافية المجزأة.

يضيف الدكتور Kapoor قائلًا: “نتطلع إلى مستقبل يتولى فيه الأفراد إدارة الشيخوخة بشكل استباقي، مدعومين بالبيانات والدقة والأسس العلمية المتينة. وLongevity+ هو مجرد البداية.”

نبذة عن BioAro
شركة BioAro Inc. هي شركة كندية متخصصة في مجال التكنولوجيا الحيوية والرعاية الصحية الدقيقة تركز على تقنيات البيانات البيولوجية المتعددة والأدوات التشخيصية المدفوعة بالذكاء الاصطناعي والطب الوقائي. تُعد شركة BioAro رائدة في دمج علم الجينوم وتكنولوجيا الأجهزة القابلة للارتداء والعلاجات المخصصة في حلول الرعاية الصحية اليومية، وتتواجد منتجاتها في جميع أنحاء كندا والولايات المتحدة ودول مجلس التعاون الخليجي وأمريكا الجنوبية والاتحاد الأوروبي والمملكة المتحدة.

عرض حصري!

في إطار التزامنا بتعزيز الصحة الشخصية، تُقدّم BioAro خصمًا حصريًا على مكملاتنا المتميزة لإطالة العمر، وذلك لمستخدمي تطبيق Biongevity على متجري Playstore وApple Store أو لزائري موقعنا الإلكتروني www.biongevity.com. ابدأ رحلتك نحو صحة أفضل اليوم!

للاستفسارات الإعلامية أو شراكات التوزيع أو لطلب عينات المنتجات، يُرجى الاتصال بـ:
جهة الاتصال الإعلامية:
Mohini
البريد الإلكتروني: [email protected]
رقم الهاتف: 2221–250–403–1+

لمزيد من المعلومات، يُرجى زيارة: www.BioAro.com | www.biongevity.com

Longevity+™ هي علامة تجارية مملوكة لشركة BioAro Inc. قيد الحصول على براءة اختراع. ولم يتم تقييم هذه البيانات من جانب الهيئات التنظيمية في جميع الولايات القضائية. لا يهدف هذا المنتج إلى تشخيص أو علاج أو شفاء أو منع أي مرض.

الصور المصاحبة لهذا الإعلان متاحة على:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b696ab44–9f1f–4fa0–89dc–e221bc2010d2

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca4969a1–f8b7–404a–a505–674b3eb975a3

https://www.globenewswire.com/NewsRoom/AttachmentNg/86acd16a–ca50–48c9–b51c–237d91e36d51


GLOBENEWSWIRE (Distribution ID 9489295)

UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health

CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) — In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch of its first nutraceutical product under its new supplement line: Longevity+™, a patent–pending, scientifically formulated capsule designed to support healthy aging through synergistic multi–molecule integration. With approvals already secured in the United Arab Emirates (UAE), BioAro is now poised for expansion into North America, Europe, the UK, and beyond.

The launch of Longevity+™ comes at a pivotal time, as the global longevity and healthy aging market is projected to surpass $44 billion by 2030, driven by growing demand for advanced nutraceuticals that go beyond basic supplementation. BioAro’s entry into this space is far from ordinary. It brings together cutting–edge research, clinical insight, and multi–omics intelligence—hallmarks of its biotech origins—to deliver a product rooted in science, not hype.

A Breakthrough, All–in–One Longevity Protocol

What sets Longevity+™ apart is not just its formulation, but its philosophy: simplicity meets synergy. Each daily dose (two capsules) contains a potent blend of Nicotinamide Mononucleotide (NMN), Resveratrol, Coenzyme Q10, Curcumin, Vitamin D, and Vitamin B12—molecules that individually support cellular energy, mitochondrial health, inflammation modulation, and cognitive clarity. But when taken together in a precisely engineered ratio, early scientific research suggest they may create synergistic effects that amplify their individual benefits—potentially offering an integrated path to extending healthspan.

“We didn't want to be just another supplement company,” says Dr. Anmol Kapoor, Founder of BioAro. “Our formulation was born from years of precision health research in genomics, metabolomics, and personalized medicine. We’ve built Longevity+ from a systems biology perspective, focusing on how molecules interact—not just how they function alone.”

From Lab to Life: A Canadian Biotech’s Global Ambition

Rooted in BioAro’s legacy of precision diagnostics and AI–driven multi–omics, the supplement line represents the company’s first consumer–facing health supplement product, translating years of complex research into a simple, daily protocol.

With regulatory clearance and market entry approval in the UAE, one of the world’s most progressive markets for health and wellness innovation, BioAro is finalizing distribution partnerships across North America, Europe, the UK, India, and Southeast Asia. The company also plans to integrate Longevity+ into its clinical longevity programs, including personalized health assessments and digital wellness tracking, forming an end–to–end ecosystem for those seeking to proactively manage aging and vitality.

What’s Inside Matters

  • NMN (Nicotinamide Mononucleotide): A powerful NAD+ precursor, vital for mitochondrial health and cellular repair.
  • Resveratrol: A polyphenol known to activate sirtuins and mimic caloric restriction benefits.
  • Coenzyme Q10: Essential for heart and energy metabolism, particularly in aging populations.
  • Curcumin: A potent anti–inflammatory and antioxidant compound from turmeric.
  • Vitamin D & B12: Crucial for immune modulation, neurocognitive health, and metabolic balance.

This formulation represents a shift toward systems–level thinking in supplementation—where the goal is not to overload the body with isolated nutrients, but to restore harmony at the molecular level.

Patent–Pending, Performance–Driven

Longevity+™ is currently under patent review for its novel combination and delivery mechanism, with BioAro leveraging its proprietary research in nutrient absorption optimization and bioavailability. Clinical pilot studies are in planning phases across Canada and the UAE, with an emphasis on biomarker tracking to validate outcomes in real–world populations.

Redefining the Future of Aging

With its entrance into the longevity supplement space, BioAro is not planning to just sell supplements, it is shaping a new narrative around aging, one where prevention and performance intersect, and where scientifically grounded strategies replace fragmented wellness advice.

“We envision a future where individuals manage aging proactively, backed by data, precision, and powerful science,” adds Dr. Kapoor. “Longevity+ is just the beginning.”

About BioAro
BioAro Inc. is a Canadian biotechnology and precision health company focused on multi–omics, AI–driven diagnostics, and preventive medicine. With a presence across Canada, USA, GCC, South America, EU, and UK, BioAro is a pioneer in integrating genomics, wearable technology, and personalized therapeutics into everyday healthcare solutions.

Exclusive Offer!

As part of our commitment to advancing personalized wellness, BioAro is offering an exclusive discount on our premium longevity supplements for users who download the app Biongevity Playstore and Apple store or visit our website at www.biongevity.com. Start your journey to better health today!

For media inquiries, distribution partnerships, or product samples, contact:
Media Contact:
Mohini
Email: [email protected]
Phone: +1–403–250–2221

For more info, please visit: www.BioAro.com | www.biongevity.com

Longevity+™ is a trademark of BioAro Inc. Patent pending. These statements have not been evaluated by regulatory bodies in all jurisdictions. This product is not intended to diagnose, treat, cure, or prevent any disease.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b696ab44–9f1f–4fa0–89dc–e221bc2010d2

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca4969a1–f8b7–404a–a505–674b3eb975a3

https://www.globenewswire.com/NewsRoom/AttachmentNg/86acd16a–ca50–48c9–b51c–237d91e36d51


GLOBENEWSWIRE (Distribution ID 9488723)

Les Émirats arabes unis approuvent le complément Longevity+ de BioAro, ouvrant la voie à un fort potentiel sur le marché mondial de la santé préventive

CALGARY, Alberta, 08 juill. 2025 (GLOBE NEWSWIRE) — Dans une avancée majeure à l’intersection de la biotechnologie, de la santé préventive et des tendances commerciales en matière de bien–être, la société canadienne de biotechnologie BioAro annonce le lancement de son tout premier produit nutraceutique, issu de sa nouvelle gamme de suppléments : Longevity+™. Cette capsule, en instance de brevet et scientifiquement formulée, vise à favoriser un vieillissement en bonne santé grâce à l'intégration synergique de plusieurs molécules. Déjà approuvé aux Émirats arabes unis (EAU), BioAro se prépare désormais à étendre sa présence en Amérique du Nord, en Europe, au Royaume–Uni, et au–delà.

Le lancement de Longevity+™ intervient à un moment clé, alors que le marché mondial de la longévité et du vieillissement en bonne santé devrait dépasser les 44 milliards de dollars d’ici 2030, porté par une demande croissante en nutraceutiques avancés allant au–delà de la supplémentation traditionnelle. L’arrivée de BioAro sur ce marché s’inscrit dans une démarche résolument innovante. Le produit allie recherche de pointe, expertise clinique et approche multi–omique, héritées directement de l’expertise biotechnologique de BioAro, pour offrir une solution fondée sur la science, loin du simple effet de mode.

Un protocole de longévité révolutionnaire et tout–en–un

Ce qui distingue Longevity+™, c'est autant sa formulation que sa philosophie : la simplicité au service de la synergie. Chaque dose quotidienne (deux gélules) renferme une synergie puissante de nicotinamide mononucléotide (NMN), resvératrol, coenzyme Q10, curcumine, vitamine D, et vitamine B12, des molécules reconnues pour leur action ciblée sur l’énergie cellulaire, la santé mitochondriale, la modulation de l’inflammation et la clarté cognitive. Pris ensemble dans un ratio précisément défini, ces composés pourraient, selon les premières recherches scientifiques, générer des effets synergiques qui renforcent leurs bienfaits respectifs, ouvrant la voie à une approche intégrée pour prolonger la santé au fil du temps.

« Nous ne voulions pas être une énième entreprise de compléments alimentaires » déclare le Dr Anmol Kapoor, fondateur de BioAro. « Cette formulation est l’aboutissement d’années de recherche avancée en santé de précision, croisant génomique, métabolomique et médecine personnalisée. Nous avons conçu Longevity+ selon une approche de biologie systémique, en nous concentrant sur les interactions entre les molécules, et non uniquement sur leurs effets isolés. »

Du laboratoire à la vie : l’ambition mondiale d’une biotech canadienne

Ancré dans l’héritage de BioAro en diagnostics de précision et analyses multi–omiques pilotées par IA, cette gamme de compléments est le premier produit de santé grand public de l’entreprise, fruit de nombreuses années de recherche transformées en un protocole quotidien facile à suivre.

Avec l’autorisation réglementaire et l’approbation pour la mise sur le marché aux Émirats arabes unis, l’un des marchés les plus avancés au monde en matière d’innovation santé et bien–être, BioAro finalise ses partenariats de distribution en Amérique du Nord, en Europe, au Royaume–Uni, en Inde et en Asie du Sud–Est. L’entreprise prévoit également d’intégrer Longevity+ dans ses programmes cliniques dédiés à la longévité, incluant des bilans de santé personnalisés et un suivi numérique du bien–être, afin de proposer un écosystème complet pour accompagner ceux qui souhaitent gérer de manière proactive leur vieillissement et leur vitalité.

Une composition qui fait toute la différence

  • NMN (nicotinamide mononucléotide) : un précurseur puissant de NAD+, essentiel pour la santé mitochondriale et la réparation cellulaire.
  • Resvératrol : un polyphénol reconnu pour activer les sirtuines et reproduire les bienfaits de la restriction calorique.
  • Coenzyme Q10 : indispensable au métabolisme cardiaque et énergétique, particulièrement chez les personnes âgées.
  • Curcumine : un puissant composé anti–inflammatoire et antioxydant extrait du curcuma.
  • Vitamines D et B12 : essentielles pour la modulation du système immunitaire, la santé neurocognitive et l’équilibre métabolique.

Cette formulation incarne une évolution vers une approche globale de la supplémentation, où l’objectif n’est pas de surcharger l’organisme en nutriments isolés, mais de rétablir l’harmonie au niveau moléculaire.

Brevet en instance, axé sur la performance

Longevity+™ fait actuellement l’objet d’un examen de brevet pour sa combinaison innovante et son mécanisme de délivrance, BioAro s’appuyant sur sa recherche propriétaire pour optimiser l’absorption des nutriments et leur biodisponibilité. Des études pilotes cliniques sont en cours de planification au Canada et aux Émirats arabes unis, mettant l’accent sur le suivi des biomarqueurs afin de valider les résultats chez des populations réelles.

Redéfinir l’avenir du vieillissement

Avec son entrée sur le marché des compléments pour la longévité, BioAro ne se contente pas de commercialiser des produits, mais façonne une nouvelle vision du vieillissement, centrée sur la prévention et l’optimisation des performances, et où des approches rigoureusement fondées sur la science supplantent les recommandations fragmentaires en matière de bien–être.

« Nous envisageons un avenir où chacun pourra gérer son vieillissement de manière proactive, grâce à des données précises, une médecine personnalisée et une science avancée », ajoute le Dr Kapoor. « Longevity+ n’est que le début. »

À propos de BioAro
BioAro Inc. est une entreprise canadienne de biotechnologie et santé de précision, spécialisée dans la multi–omique, les diagnostics pilotés par IA et la médecine préventive. Avec une présence au Canada, aux États–Unis, dans le Golfe (GCC), en Amérique du Sud, en Europe et au Royaume–Uni, BioAro se positionne en leader dans l’intégration de la génomique, des technologies portables et des thérapies personnalisées au service de la santé au quotidien.

Offre exclusive !

Dans le cadre de notre engagement pour le bien–être personnalisé, BioAro propose une remise exclusive sur ses compléments premium pour la longévité, réservée aux utilisateurs téléchargeant l’application Biongevity sur le Playstore ou l’Apple Store, ou visitant notre site web www.biongevity.com. Prenez votre santé en main dès aujourd’hui !

Pour toute demande média, partenariat de distribution ou échantillon produit, veuillez contacter :
Contact presse :
Mohini
E–mail : [email protected]
Téléphone : +1–403–250–2221

Pour en savoir plus, rendez–vous sur : www.BioAro.com | www.biongevity.com

Longevity+™ est une marque déposée de BioAro Inc. Brevet en cours d’homologation. Ces déclarations n’ont pas été évaluées par les autorités réglementaires dans toutes les juridictions. Ce produit n’entend pas diagnostiquer, traiter, guérir ni prévenir quelconque maladie.

Des photos accompagnant ce communiqué sont disponibles au :

https://www.globenewswire.com/NewsRoom/AttachmentNg/b696ab44–9f1f–4fa0–89dc–e221bc2010d2

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca4969a1–f8b7–404a–a505–674b3eb975a3

https://www.globenewswire.com/NewsRoom/AttachmentNg/86acd16a–ca50–48c9–b51c–237d91e36d51


GLOBENEWSWIRE (Distribution ID 9489295)